Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. (Q30444892)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. (English)

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

Bärbel-Maria Kurth

6

object named as

B M Kurth

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

1 reference

ORCID Public Data File 2021

author name string

U Siebert

1

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

G Sroczynski

2

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

S Rossol

3

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

U Ravens-Sieberer

5

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

M P Manns

7

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

J G McHutchison

8

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

J B Wong

9

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

German Hepatitis C Model (GEHMO) Group

10

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

International Hepatitis Interventional Therapy (IHIT) Group

11

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

language of work or name

0 references

publication date

1 March 2003

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

52

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

3

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

425-432

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Costs of hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Modeling the hepatitis C virus epidemic in France

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Gains in life expectancy from medical interventions--standardizing data on outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Economic analysis alongside clinical trials. Bias in the assessment of economic outcomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

An analysis of liver transplant experience from 37 transplant centers as reported to Medicare.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

The Markov process in medical prognosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

20 June 2018

Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

26 November 2018

Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

26 November 2018

Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

26 November 2018

High-priced technology can be good value for money.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

26 November 2018

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

26 November 2018

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

26 November 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

26 November 2018

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

26 November 2018

Health assessment for chronic HCV infection: results of quality of life.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

26 November 2018

Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

26 November 2018

Markov models in medical decision making: a practical guide.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

26 November 2018

Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

26 November 2018

Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1773554

26 November 2018

EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimating future hepatitis C morbidity, mortality, and costs in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Visual analog scales: do they have a role in the measurement of preferences for health states?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural course of chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis. Survival and prognostic factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amniocentesis or chorionic villus sampling for prenatal genetic testing: a decision analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lebertransplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sclerotherapy for male alcoholic cirrhotic patients who have bled from esophageal varices: results of a randomized, multicenter clinical trial. The Veterans Affairs Cooperative Variceal Sclerotherapy Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12584228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/GUT.52.3.425

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30444892&oldid=1590407193"